2017
DOI: 10.1080/09537104.2017.1294681
|View full text |Cite
|
Sign up to set email alerts
|

Development of quantitative monoclonal antibody-specific immobilization of platelet antigens assay for antibodies against human platelet antigen-1a, 3a, and 5b

Abstract: Human platelet antigens (HPAs) are platelet-specific alloantigens that cause alloimmunization. Alloantibodies induced via pregnancy and transfusion may result in various clinical syndromes. The monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay is the gold standard for the detection and identification of HPA antibodies. The present study aimed to develop standardized quantitative MAIPA assays for antibodies against HPA-1a, 3a, and 5b. MAIPA protocol was applied on serial dilutions o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 15 publications
0
3
0
Order By: Relevance
“…At present, the recommendation of prenatal diagnosis procedures for FAIT are as follows: first, fetal HPAs typing is detected in maternal, paternal serum and amniotic fluid to analyze whether there is HPAs incompatibility; then it is recommended to use monoclonal antibody immobilization of platelet specific antigen assay (MAIPA) to analyze and identify maternal platelet specific alloantibodies, or to detect maternal serum autoantibodies. [8][9][10] Limited by the advanced skills and costs, non-invasive prenatal diagnosis technology has not been universally available in China and there is few cases of FAIT can be successfully diagnosed prenatally and received intervention.…”
Section: Discussionmentioning
confidence: 99%
“…At present, the recommendation of prenatal diagnosis procedures for FAIT are as follows: first, fetal HPAs typing is detected in maternal, paternal serum and amniotic fluid to analyze whether there is HPAs incompatibility; then it is recommended to use monoclonal antibody immobilization of platelet specific antigen assay (MAIPA) to analyze and identify maternal platelet specific alloantibodies, or to detect maternal serum autoantibodies. [8][9][10] Limited by the advanced skills and costs, non-invasive prenatal diagnosis technology has not been universally available in China and there is few cases of FAIT can be successfully diagnosed prenatally and received intervention.…”
Section: Discussionmentioning
confidence: 99%
“…Since the 2016 Workshop, very few studies on the development of novel anti-platelet antibody detection techniques, or optimization of existing methods, have been published. Li et al [9] have worked on the optimization and quantification of anti-HPA-1a, anti-HPA-3a and anti-HPA-5b by MAIPA assay using standards or reference reagents. They were able to optimize conditions to obtain good sensitivity, reproducibility and specificity.…”
Section: Discussionmentioning
confidence: 99%
“…The detailed MAIPA protocols are however not harmonized, and the number of platelets used, the monoclonal antibodies for glycoprotein capture as well as lysis, incubation and washing steps vary among laboratories: according to the ISBT workshop report from 2018 [18], most of the reference laboratories report the use of in-house MAIPA, while a few laboratories use a commercial MAIPA kit (ApDia, Turnhout, Belgium). Quantitative MAIPA for anti-HPA-1a has been used for decades [19,20] and recently also reported for anti-HPA-3a and anti-HPA-5b [21].…”
Section: Identification Of Glycoprotein-specific Antibodiesmentioning
confidence: 99%